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Although angiotensin-converting enzyme (ACE) inhibitors are
well-established drugs in the treatment of hypertension, they
are not supposed to be sufficient in the inhibition of
aldosterone formation. The present study analyzes the effect
of aldosterone receptor antagonist, spironolactone and ACE
inhibitor, captopril on nitric oxide (NO) and S-nitrosothiol
formation in the kidney of NG-nitro-L-arginine methyl ester
(L-NAME)-treated rats. Male Wistar rats were divided into six
groups: (1) controls, (2) L-NAME (40 mg/kg/day), (3)
spironolactone (200 mg/kg/day), (4) captopril (100 mg/kg/day),
(5) L-NAMEþ spironolactone, and (6) L-NAMEþ captopril. After
4 weeks, NO synthase (NOS) activity, protein expression of
endothelial NOS, inducible NOS and concentration of thiol and
S-nitrosothiol groups were determined in the kidney. Besides
the increase in systolic blood pressure (by 32%) and the
decrease in NOS activity (by 37%), L-NAME treatment lowered
the concentration of thiols (by 32%) and S-nitrosothiols (by
36%) in the renal tissue. Simultaneous treatment with
spironolactone preserved NOS activity and S-nitrosothiols on
the control level, whereas captopril did not affect these
parameters modified by L-NAME treatment. Moreover,
spironolactone increased expression of endothelial NOS
protein without affecting inducible NOS protein expression.
In conclusion, both captopril and spironolactone prevented
L-NAME-induced hypertension and the decline of the
antioxidant potential of the kidney tissue. However, only
spironolactone improved NOS activity which led to the
S-nitrosothiols formation. Both NO itself and S-nitrosothiols
may contribute to the preventive effect of spironolactone
against development of L-NAME-induced hypertension.
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Although angiotensin-converting enzyme (ACE) inhibitors
and angiotensin type 1 (AT1) receptor antagonists are well
established drugs in the protection of the cardiovascular
system during chronic heart failure and hypertension,1 the
potential protective role of aldosterone receptor antagonists
is being investigated only in the recent years.2,3 This interest
is associated with unexpectedly positive result of the
Randomized Aldacton Evaluation Study involving patients
with severe chronic heart failure, which has shown 30%
reduction of mortality, when aldosterone receptor antagonist,
spironolactone was added to the standard treatment with
ACE inhibitors.4 ACE inhibitors are supposed, at least in
some cases, not to be sufficient to inhibit aldosterone
formation. This escape of aldosterone synthesis from the
effect of ACE inhibitors is associated with the fact that
aldosterone production is, besides angiotensin II, regulated
by several other factors as glucocorticoid and potassium
level.5
Data are available that spironolactone can, besides
myocardium and vessel protection, attenuate the undesirable
effect of renin–angiotensin–aldosterone system on the kidney.
The reduction of proteinuria and nephrosclerosis was
observed both in animal experiment6 and in patients with
chronic renal failure.7 Moreover, aldosterone, similarly as
angiotensin II and catecholamines, has been shown to induce
oxidative stress by activation of nicotinamide adenine
dinucleotide phosphate (reduced form) oxidase.8 The renal
effects, including the reduction of reactive oxygen species form-
ation, may contribute to the overall effects of aldosterone
receptor blockers such as spironolactone.
The model of NG-nitro-L-arginine methyl ester (L-NAME)-
induced hypertension, besides decreased nitric oxide (NO)
production and increased oxidative stress,9 is char-
acterized by left ventricular hypertrophy, fibrosis,10,11 and
deterioration of kidney structure and function.12 One of
the important metabolic pathways, which is operating in the
renal tissue, is the formation of thiol and S-nitrosothiol
groups, which are known to possess several important
properties including antioxidant and vasorelaxant
potential.13,14
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We therefore investigated whether aldosterone receptor
antagonist, spironolactone, can beneficially interfere with the
L-NAME-induced hypertension and ameliorate the altera-
tions in thiol and S-nitrosothiol group formation. We
compared the effect of spironolactone with thiol group
containing ACE inhibitor, captopril.
RESULTS
Cardiovascular parameters
Systolic blood pressure (SBP) was not significantly different
in the six groups of rats before the beginning of the treatment
(Figure 1). In the control group, SBP did not change
significantly during the experiment. Treatment of rats with
L-NAME (40 mg/kg/day) for 4 weeks induced a progressive
increase in SBP (32% after 4 weeks of treatment as compared
to SBP of the control rats, Po0.05). Administration of
spironolactone (200 mg/kg/day) alone had no effect on SBP,
whereas captopril treatment produced a decrease of SBP
below the control level with the significant difference starting
from the second week of treatment. The increase in SBP
induced by L-NAME was significantly lowered by concomi-
tant treatment with spironolactone. Concomitant treatment
with L-NAME plus captopril maintained the SBP at the level
corresponding to untreated controls (Figure 1).
Body weight (BW) was not significantly different among
particular experimental groups (i.e. control, L-NAME, spirono-
lactone, spironolactoneþ L-NAME, captopril, captoprilþ
L-NAME). Chronic administration of L-NAME alone
induced an increase in left ventricle weight/BW ratio without
a significant change in right ventricle weight/BW or left
kidney weight/BW ratio. Administration of either spirono-
lactone or captopril alone did not affect left ventricle weight/
BW, right ventricle weight/BW or left kidney weight/BW
ratio. Chronic administration of spironolactone or captopril
together with L-NAME prevented the left ventricle
hypertrophy development caused by L-NAME treatment
(Table 1).
Total NO synthase activity and Western blot analysis
In the kidney samples taken from the control group, total NO
synthase (NOS) activity was 16.971.1 pkat/g protein.
L-NAME treatment decreased total NOS activity by 37%
(Po0.05). On the other hand, both spironolactone and
captopril increased total NOS activity above the control level
(Po0.05). Simultaneous sprironolactone and L-NAME
treatment kept total NOS activity on the control level,
whereas captopril did not affect the activity decreased by
L-NAME treatment (Figure 2).
The endothelial NOS (eNOS) protein expression of
L-NAME-treated and spironolactone-treated rats was elevated
significantly by 45% (Po0.05) and 90% (Po0.05), respec-
tively, compared to the controls, with the additive effect in
spironolactoneþ L-NAME-treated group. Captopril did not
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Figure 1 | Effect of 4-week L-NAME, spironolactone, L-NAMEþ
spironolactone, captopril, and L-NAMEþ captopril treatment on
SBP. Ctrl – control, LN – 40 mg/kg/day L-NAME, S – spironolactone
200 mg/kg/day, SL – L-NAMEþ spironolactone in corresponding
doses, C – captopril 100 mg/kg/day, CL – L-NAMEþ captopril in
corresponding doses. Significant differences: *Po0.05 compared to
controls, þPo0.05 compared to L-NAME group.
Table 1 | BW, LVW/BW and LKW/BW and glomerular density (N) in rats treated with L-NAME, spironolactone, captopril and
L-NAME simultaneously with spironolactone or captopril during 4 weeks
Control L-NAME Spironol Spironol+L-NAME Captopril Captopril+L-NAME
BW (g) 390710 405715 378712 370716 385712 394713
LVW/BW (mg/g) 1.3370.04 1.6470.05* 1.1970.06 1.3570.05+ 1.2570.05 1.3270.08+
LKW/BW (mg/g) 3.4570.06 3.5070.07 3.4970.08 3.5670.10 3.3170.07 3.4270.08
N (1/mm2) 9.4470.23 7.9670.30* 8.9270.25 9.5870.50 9.3470.30 8.8870.26
BW, body weight; LKW, left kidney weight; L-NAME, NG-nitro-L-arginine methyl ester; LVW, left ventricle weight.
Data are means7s.e.m., significant differences.
*Po0.05 compared to controls.
+Po0.05 compared to L-NAME group.
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Figure 2 | Effect of 4-week L-NAME, spironolactone, L-NAMEþ
spironolactone, captopril, and L-NAMEþ captopril treatment on
NOS activity in the kidney. Ctrl – control, LN – 40 mg/kg/day
L-NAME, S – spironolactone 200 mg/kg/day, LS – L-NAMEþ
spironolactone in corresponding doses, C – captopril 100 mg/kg/day,
LC – L-NAMEþ captopril in corresponding doses. *Po0.05
compared to control, þPo0.05 compared to L-NAME group.
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affect eNOS protein expression (Figure 3). There were no
significant changes in inducible NOS (iNOS) protein
expression within the groups (Figure 4).
Thiol and S-nitrosothiol group concentration
In the kidney samples taken from the control group, thiol
group concentration was 6.070.4 mmol/g tissue. L-NAME
treatment decreased this concentration by 32% (Po0.05).
Both spironolactone and captopril increased thiol group
concentration by 31% (Po0.05) and 48% (Po0.05),
respectively. Simultaneous spironolactone or captopril with
L-NAME treatment was able to eliminate the effect of
L-NAME (Figure 5).
In the kidney samples taken from the control group,
S-nitrosothiol group concentration was 1.1070.08 mmol/g
tissue. L-NAME treatment decreased this concentration by
36% (Po0.05). Similarly as thiol group concentration, both
spironolactone and captopril increased S-nitrosothiol group
concentration by 45% (Po0.05) and 55% (Po0.05), respect-
ively. While simultaneous spironolactone and L-NAME
treatment kept S-nitrosothiol group concentration in the
control level, captopril did not affect the concentration decreased
by L-NAME (Figure 6).
Morphometric analysis of glomeruli
Results are summarized in the Table 1. The relative kidney
weight was unchanged in either group. L-NAME-treated rats
showed a reduction in glomerular numerical density
(Po0.05), which was prevented by both spironolactone
and captopril treatment.
DISCUSSION
The present study demonstrated that besides the increase in
blood pressure and the decrease of NOS activity in the
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Figure 3 | Effect of 4-week L-NAMEþ spironolactone, L-NAMEþ
spironolactone, captopril, and L-NAMEþ captopril treatment
on eNOS and b-actin expression in the kidney. Ctrl – control,
LN – 40 mg/kg/day L-NAME, S – spironolactone 200 mg/kg/day,
LS – L-NAMEþ spironolactone in corresponding doses,
C – captopril 100 mg/kg/day, LC – L-NAMEþ captopril in
corresponding doses. *Po0.05 compared to control, þPo0.05
compared to L-NAME group.
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Figure 4 | Effect of 4-week L-NAME, spironolactone, L-NAMEþ
spironolactone, captopril, and L-NAMEþ captopril treatment
on iNOS and b-actin expression in the kidney. Ctrl – control,
LN – 40 mg/kg/day L-NAME, S – spironolactone 200 mg/kg/day,
LS – L-NAMEþ spironolactone in corresponding doses,
C – captopril 100 mg/kg/day, LC – L-NAMEþ captopril in
corresponding doses.
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Figure 5 | Effect of 4-week L-NAME, spironolactone, L-NAMEþ
spironolactone, captopril, and L-NAMEþ captopril treatment on
thiol group concentration in the kidney. Ctrl – control, LN – 40 mg/
kg/day L-NAME, S – spironolactone 200 mg/kg/day, LS – L-NAME-
spironolactone in corresponding doses, C – captopril 100 mg/kg/day,
LC – L-NAMEþ captopril in corresponding doses. *Po0.05 compared
to control, þPo0.05 compared to L-NAME group.
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Figure 6 | Effect of 4-week L-NAME, spironolactone, L-NAMEþ
spironolactone, captopril, and L-NAMEþ captopril treatment on
S-nitrosothiol group concentration in the kidney. Ctrl – control,
LN – 40 mg/kg/day L-NAME, S – spironolactone 200 mg/kg/day,
LS – L-NAMEþ spironolactone in corresponding doses,
C – captopril 100 mg/kg/day, LC – L-NAMEþ captopril in
corresponding doses. *Po0.05 compared to control, þPo0.05
compared to L-NAME group.
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kidney, L-NAME treatment resulted in an attenuated level of
thiols and S-nitrosothiols in the renal tissue. Simultaneous
treatment with both the aldosterone antagonist, spironolac-
tone and ACE inhibitor, captopril prevented the development
of hypertension and the diminution of thiol groups in renal
tissue. Yet, only spironolactone prevented the depression of
NOS activity and S-nitrosothiol concentration in the kidney.
The increased expression of endothelial NOS protein induced
by spironolactone treatment may account for this effect.
The important question is the dose of spironolactone and
captopril that should be chosen to counteract the patho-
logical alterations induced by L-NAME. Forty milligrams per
kilogram of L-NAME used in this experiment, on the basis of
our previous studies, seems to be the sufficient dose able to
induce hypertension, concomitant left ventricular hyper-
trophy and fibrosis, and vascular remodeling and dys-
function.10,11,15 On the other hand, 100 mg/kg/day of
captopril10,11,16 and 200 mg/kg/day of spironolactone,17,18
used in previous works, were shown to lower increased blood
pressure and protect the cardiovascular system against
deleterious effect of hemodynamic overload. Moreover, the
higher dose of captopril (150 mg/kg/day) or spironolactone
(300 mg/kg/day), which were tested in our pilot studies, was
not well tolerated, as convulsions of striated muscles
frequently occurred, presumably as a result of hyperkaliemia.
Thus, use of the lowest effective dose of L-NAME (40 mg/kg/
day) and of the tolerable pharmacological dose of captopril
(100 mg/kg/day) and spironolactone (200 mg/kg/day) may be
predicted to induce the potential protective effect of tested
substances.
To inhibit angiotensin II formation, captopril was chosen
from several reasons. Differently to most other ACE
inhibitors, captopril is not a prodrug but the active substance
itself and to become active it does not need any further
processing in the liver. Second, captopril is the ACE-inhibitor
involving thiol group, which might participate in the thiols
formation and therefore it may have stronger antioxidant
effect than other ACE-inhibitors.19 Third, we have sufficient
experiences from several previous experiments in using
captopril to prevent or regress the organ damage of the
L-NAME-induced hemodynamic overload.10,11,16,20
Both captopril and spironolactone were previously shown
to improve endothelial dysfunction in different models of
haemodynamic overload. Captopril decreased blood pressure
and improved NO-dependent relaxation of aorta in heredi-
tary hypertriglyceridemic rats.21 In rats with chronic heart
failure, aldosterone receptor antagonist, eplerenone improved
NO-mediated relaxation of the aorta.22 Quaschning et al.23
demonstrated that eplerenone and spironolactone normal-
ized blood pressure, prevented upregulation of vascular
endothelin-1 and restored NO-mediated endothelial dysfunc-
tion in liquorice-induced hypertension. In L-NAME-induced
hypertension, Pereira and Mandarim-de-Lacerda24 documen-
ted the preventive effect of spironolactone against increased
blood pressure and diminution of vessel density in the heart.
However, the mechanism of improvement of endothelial
dysfunction and blood pressure reduction seems to be
different for captopril and spironolactone. Spironolactone
increased both NOS activity and eNOS protein expression in
the kidney, resulting supposedly in enhanced NO production.
On the other hand, captopril failed to attenuate the
inhibition of renal NOS activity induced by L-NAME.
In agreement with this finding, we have previously shown
in the same model of hypertension that captopril was not
successful in improvement of NOS activity in the left
ventricle, aorta, or brain.16 Similarly, in L-NAME model of
hypertension, imidapril prevented hypertrophy of the left
ventricle and nephrosclerosis, yet without improving the
depressed nitrate/nitric production.25 It has been suggested
that cardiovascular protection via ACE inhibition may be
caused by mechanisms not involving the improvement of NO
production.10,26
Both drugs in our experiment increased the concentration
of thiol groups in the kidney. It has previously been suggested
that rapidity of NO reaction with molecular oxygen, super-
oxide anion, or with heme and non-heme iron can be
attenuated by the stabilization of NO by a carrier molecule
that preserves its biological activity. Thiol groups were
revealed to be mainly responsible for this effect.27 Thiol
groups may protect NO molecule from oxidation by
scavenging free radicals27–29 and forming nitrosothiols.13,14
Both these effects can prolong NO half-life and potentiate its
vasorelaxant effect. However, only spironolactone increased
concentration of nitrosothiols groups in our experiment. The
fact that captopril failed to enhance S-nitrosothiol groups in
the kidney may be associated with the disability of this drug
to increase production of NO molecules, which could react
with thiol groups converting them to S-nitrosothiols. Thus,
the prominent reduction of blood pressure by captopril may
be more plausibly explained by reduction of angiotensin II
formation than by increased NO formation. This presump-
tion is supported by an increased renin level in plasma29–31
and ACE activity detected in the heart and coronary artery31
in L-NAME-induced hypertension and by the ability of ACE
inhibitors to reduce myocardial remodeling in this particular
model.31
On the other hand, spironolactone elevated both NOS
activity by increasing endothelial NOS protein expression
and thiol group concentration probably by inhibiting
aldosterone formation. The increase in NO and S-nitro-
sothiol production may contribute to the vasorelaxant
properties of spironolactone. The increase in vasorelaxant
capacity may be responsible for the preventive effect of
spironolactone against development of hypertension.
Similarly, eplerenone-induced endothelial NOS gene
expression in the heart, aorta, and kidney was associated
with reduction of SBP and cardiac and renal damage
produced by two-kidney, one-clip renovascular hypertension
in rats.32 Moreover, spironolactone added to the ACE
inhibitors normalized NO-mediated relaxation in experi-
mental chronic heart failure by beneficial modulation of the
balance between NO and superoxide anion formation33 and
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reduced blood pressure during development of diabetic
hypertension.34
The iNOS protein expression was not changed either by
L-NAME or by captopril or spironolactone treatment in
comparison with the control group. The fact that iNOS was
expressed also in the renal tissue of controls is in agreement
with findings of several other authors35,36 who indicated that
iNOS was expressed in the normal kidney not affected by a
pathologic process, mainly in the tissue of tubules.
It was shown in previous works with the model of
L-NAME-induced hypertension37 that there was a fibrosis in
the renal cortex associated with hypertrophy of the resting
glomeruli. This histological alteration was associated with
deterioration of glomerular filtration rate12,38 and a corre-
sponding increase in creatinine and urea concentration in
plasma.12 Angiotensin type 1 antagonist losartan38 or ACE
inhibitor ramipril12,39 prevented these alterations.
Investigation of kidney function was beyond the scope of
our study. However, we have shown that the glomerulus
density in the renal cortex was decreased in L-NAME-treated
rats, what potentially might be associated with a reduction of
glomerular filtration function. Addition of either captopril or
spironolactone prevented the reduction of glomeruli in the
renal cortex. This protective effect of both drugs could, at
least in part, go into the account of their antioxidant
potential linked with preservation of thiol and/or S-nitroso-
thiol groups. To show, whether there are some differences
between captopril and spironolactone with respect to
the level of kidney protection would require more subtle
methods such as the investigation of glomerular filtration
rate or endothelium-dependent vascular relaxation of renal
and other small arteries.
We conclude that both captopril and spironolactone
prevented L-NAME-induced hypertension and the decline
of the antioxidant potential of the kidney tissue. However,
only spironolactone improved NOS activity which led to the
nitrosothiols formation. Both NO itself and S-nitrosothiols
may contribute to the preventive effect of spironolactone
against development of L-NAME-induced hypertension.
MATERIALS AND METHODS
Chemicals and drugs
All the chemicals used were purchased from Sigma-Aldrich Chmie,
(GmbH, Munich, Germany) except of [3H]-L-arginine (Amersham
Biosciences, Buckinghamshire, UK).
Animals and treatment
All procedures and experimental protocols were approved by the
Ethical Committee of the Institute of Normal and Pathological
Physiology SAS, and conform to the European Convention on
Animal Protection and Guidelines on Research Animal Use.
Male Wistar rats, 12-week-old, were randomly divided into six
groups (n¼ 8 in each group): the control group, the group receiving
L-NAME in the dose of 40 mg/kg/day, the group receiving
aldosterone receptor antagonist, spironolactone in the dose of
200 mg/kg/day alone or simultaneously with L-NAME, and the
group receiving ACE inhibitor, captopril in the dose of 100 mg/kg/
day alone or simultaneously with L-NAME during 4 weeks. L-NAME
and captopril were administered via the drinking water. Spirono-
lacton was mixed as an emulsion and was applied via a gavage twice
daily. Moreover, all other animals were gavaged with placebo twice
daily in order that the same handling conditions were preserved for
all animals in the experiment. Daily water consumption was
estimated individually for every animal 1 week before the
experiment. During the experiment, drinking fluid consumption
was controlled and adjusted, if necessary. All animals were housed at
a temperature of 22–241C, in individual cages and fed with a regular
pellet diet ad libitum. SBP was measured by non-invasive tail-cuff
plethysmography twice a week. After 4 weeks of treatment, the
animals were killed and BW, heart weight, left ventricle weight, right
ventricle weight, and left kidney weight were determined. The left
ventricle weight/BW, right ventricle weight/BW, and left kidney
weight/BW ratios were calculated. At the end of the experiment total
NOS activity, expression of endothelial and inducible NOS protein
as well as concentration of thiol and S-nitrosothiol groups were
determined in the kidney.
Total NOS activity and Western blot analysis
Total NOS activity was determined in crude homogenates of the
kidney by measuring the formation of [3H]-L-citrulline from [3H]-L-
arginine as previously described by Bredt and Snyder40 with minor
modifications.10 Total NOS activity was expressed as pkat/g of
proteins.
Samples of the kidney were homogenized in 25 mmol/l Tris-HCl,
pH 7.4, containing 5 mmol/l ethylene diaminetetraacetic acid,
50 mmol/l NaCl, 1 mmol/l leupeptin, 0.3 mmol/l aprotinin,
0.1 mmol/l phenyl methylsulfonyl fluoride, 1 mmol/l gestating, and
1% sodium dodecyl sulfate. After the centrifugation (15 000 g,
20 min, twice) supernatants were subjected to sodium dodecyl
sulfate-polyacrylamide gel electrophoresis using 10% gels. Following
the electrophoresis, proteins were transferred to nitrocellulose
membranes and were probed with a polyclonal rabbit antibodies
against eNOS or iNOS (Alexis Biochemicals, Grunberg, Germany).
Bound antibodies were detected using a secondary peroxidase-
conjugated anti-rabbit antibody (Alexis Biochemicals, Grunberg,
Germany). The bands were visualized using the enhanced chemi-
luminescence system (ECL, Amersham, UK) and analyzed densito-
metrically using Photo-Capt V.99 software.
Thiol and S-nitrosothiol group concentration
The concentration of thiol groups were determined by the method
of Ellman detecting low molecular weight thiols in their reduced
form.41 Briefly, the excised samples of kidney were homogenized
immediately in 0.5 vol. of ice-cold 5% sulfosalicylic acid solution.
After centrifugation at 12 000 g for 15 min, the thiol levels in the
acid-soluble fractions were determined using Ellman’s reagent and
measured spectrophotometrically at 412 nm (GBC 911A; Bio-Rad
Laboratories, GambH, Vien, Austria).
S-nitrosothiol levels were determined by the method of Saville42
and Tietze.43 Briefly, ethanol was added to kidney samples in a final
concentration of 30%. After homogenization, the samples were
centrifuged at 12 000 g for 5 min, and the ethanol-soluble fractions
were measured for S-nitrosothiol levels. Twenty milliliters 1.0%
ammonium sulfamate was then added to 500 ml of ethanol-soluble
fractions. This was followed by additions of 0.1 ml of 0.5 M HCl
containing 0.3% HgCl2 and 4.6% sulfanilamide and 150 ml of 0.5 M
HCl containing 0.2% N-1-naphthyl-ethylenediamine dihydrochlor-
ide. After incubation for 30 min at 251C, the concentration of
174 Kidney International (2006) 70, 170–176
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S-nitrosothiols was determined via spectrophotometry at 550 nm
(Bio-Rad, GBC 911A) using nitrosoglutathione as a standard. No
appreciable decomposition of the standard nitrosoglutathione
occurred during the course of the assay.
Determination of thiol as well as S-nitrosothiol levels was carried
out according to the modifications of Minamiyama et al.44
Morphometric analysis of glomeruli in the kidney cortex
Kidneys were removed and weighed. The morphometrical analysis
was performed as described by Pereira and Mandarim-de-Lacerda37
with minor modifications. Renal fragments were routinely fixed in
formaldehyde, sectioned at 10 mm thick and stained with hematox-
ylin–eosin staining. Using CCD camera coupled to PC equipped
with morphometric software (Impor 4.0, Kvant, Slovakia) the
glomerular numerical density per area (N) was determined by
observing 10 microsopic fields per animal (100 per group).
Glomeruli were counted in a frame of 1 mm2, only considering
well-perserved structures and not counting any that were not
completely within our defined 1 mm2 area.
Statistical analysis
The results are expressed as mean7s.e.m. One-way analysis of
variance and Bonferroni’s test were used for statistical analysis.
Values were considered to differ significantly if the probability value
was less than 0.05.
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